Skip to Content
  • Things I Won't Work With

    Things I Won’t Work With: Ozonides

    I’ve never done an ozone reaction myself. In fact, I haven’t seen anyone else do an ozonolysis in years now, and I wonder if this reaction is passing into chemical history. These guys are hoping not.) Many chemistry departments have an electric gizmo to produce ozone in small quantities, and I get the impression that… Read More
  • Patents and IP

    Keep It To Yourself

    I’ve mentioned how patentability can be ruined by any sort of prior publication, but – since we’re talking about the law, after all – there’s always room to argue about what a “publication” might be. That’s been clarified a bit by the recent In re Klopfenstein decision, available herein all its legal… Read More
  • Patents and IP

    I’ll Have the Lot

    Thanks to the Patnews mailing list, I was made aware of an alarming patent application from Genentech … Read More
  • Patents and IP

    Alexander Would Have Understood

    You’d think that by now most reasonably simple chemical structures would have been explored, but it’s funny how many untouched areas still exist. I was looking at one the other day, which I certainly can’t specify, but it surprised me that such a small “drug-like” template hadn’t been worked on. I expected to see… Read More
  • Drug Prices

    Cui Bono?

    Holman Jenkins has an interesting “Business World” column in today’s Wall Street Journal. Writing about Merck and Vioxx, he wonders: “Did CEO Ray Gilmartin blunder in withdrawing Vioxx from the market? Merck executives yanked the prescription pain reliever, amid much backpatting, when a study revealed that long-term users we… Read More
  • Academia (vs. Industry)

    Gumming Up the Amyloid Works

    The October 29th issue of Science has an interesting article from a team at Stanford on a possible approach for Alzheimer’s therapy. The dominant Alzheimer’s hypothesis, as everyone will probably have heard, is that the aggregation of amyloid protein into plaques in the brain is the driving force of the disease. There’s some well- Read More
  • Drug Industry History

    Merck’s State of Mind

    It may not be known outside the industry, but what Merck is going through right now must be particularly painful just because it’s happening to Merck. Now, as I mentioned the other day, I have a lot of respect for the company and for many of the people who work there. (See “Let’s See What… Read More
  • The Scientific Literature

    Take it Off!

    When I was an undergraduate, learning all the chemical reactions that you have to learn in undergraduate courses, I got a few wrong ideas into my head. Well, probably more than a few, but you know what I mean. One of them came from Theodora Greene’s book on protecting group chemistry, which was a new… Read More
  • Life in the Drug Labs

    A Visit To Academia

    I gave a talk on drug discovery at a local university yesterday, which was an interesting trip. The labs were in a new building, and were quite nice. (I hope that Duke has renovated the labs I worked in during grad school, but I haven’t heard that they have. . .if not, they must be… Read More
  • Business and Markets

    Don’t Ask; Just Trade

    At the risk of perpetuating the idea that my support of Bush was purely economic, it’s worth noting that his re-election had an immediate impact on the pharmaceutical stocks. The exception was the stock of companies closely identified with stem cell research. I should have gone short, darn it all. You have three reasonably pure… Read More